New and Emerging Antifungal Agents

Hogan LH, Klein BS, Levitz SM. Virulence factors of medically important fungi. Clin Microbiol Rev 1996 Oct; 9(4): 469–88 Wheat J. Histoplasmosis: experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore) 1997 Sep; 76(5): 339–54 Denning DW. Invasive aspergillosis. Clin Infect Dis 1998 Apr; 26(4): 781–803 Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7Suppl. 2: 8–24 Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991; 13: 1163–9 Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the Acquired Immunodeficiency Syndrome. N Engl J Med 1989; 321(12): 794–9 Cameron ML, Bartlett JA, Gallis HA, et al. Manifestations of pulmonary cryptococcosis in patients with Acquired Immunodeficiency Syndrome. Rev Infect Dis 1991; 13: 64–7 Hajjeh RA, Conn LA, Stephens DS, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 1999 Feb; 179(2): 449–54 Vilchez RA, Linden P, Lacomis J, et al. Acute respiratory failure associated with pulmonary cryptococcosis in non-AIDS patients. Chest 2001 Jun; 119(6): 1865–9 Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000 Apr; 30(4): 653–7 Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990 Mar; 12(2): 308–29 Rogers PD, Jenkins JK, Chapman SW, et al. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis 1998 Dec; 178(6): 1726–33 Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Med Mycol 2000; 38Suppl. 1: 335–47 Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002 Jan; 49Suppl. A: 7–10 Friese G, Discher T, Fussle R, et al. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 2001 Nov; 15(17): 2344–5 Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998 Sep; 27(3): 603–18 Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001 Jul; 20(7): 460–6 Mills W, Chopra R, Linch DC, et al. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994 Apr; 86(4): 754–60 Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995 May; 155(10): 1093–8 White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997 Apr; 24(4): 635–42 Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997 Sep; 98(3): 711–8 Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998 Oct; 103(1): 205–12 Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 Mar; 340(10): 764–71 Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001 Dec; 45(12): 3487–96 Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 1998 Sep; 18(5): 1053–61 Bennett J. Editorial response: choosing amphotericin B formulations -between a rock and a hard place. Clin Infect Dis 2000 Nov; 31(5): 1164–5 Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000 Nov; 31(5): 1155–63 Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents 2001 Mar; 17(3): 161–9 Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999 Dec; 29(6): 1402–7 Schmitt HJ, Bernard EM, Hauser M, et al. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988 Nov; 32(11): 1676–9 Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001 Sep; 33(5): 629–40 Calvo V, Borro JM, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999 May; 115(5): 1301–4 Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997 Feb; 29(1–2): 627–8 Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999 Jun; 93(11): 3654–61 Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001 Aug; 72(3): 545–8 Niki Y, Bernard EM, Schmitt HJ, et al. Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother 1990 Jan; 34(1): 29–32 Dubois J, Bartter T, Gryn J, et al. The physiologic effects of inhaled amphotericin B. Chest 1995 Sep; 108(3): 750–3 Gryn J, Goldberg J, Johnson E, et al. The toxicity of daily inhaled amphotericin B. Am J Clin Oncol 1993 Feb; 16(1): 43–6 Cicogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997 Feb; 41(2): 259–61 Allen SD, Sorensen KN, Nejdl MJ, et al. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non- liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994 Dec; 34(6): 1001–13 Ruijgrok EJ, Vulto AG, Van Etten EW. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 2001 Jul; 48(1): 89–95 Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies: U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901–11 Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guideline for the treatment of coccidioidomycosis: Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30(4): 658–61 Chapman SW, Bradsher Jr RW, Campbell Jr GD, et al. Practice guidelines for the management of patients with blastomycosis: Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30(4): 679–83 Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis: Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30(4): 688–95 Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus: Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30(4): 696–709 Boogaerts MA, Maertens J, Van Der Geest R, et al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother 2001 Mar; 45(3): 981–5 Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001 Oct; 33(8): 83–90 Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001 Sep; 135(6): 412–22 Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001 Nov; 26(8): 648–53 Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997 Apr; 41(4): 841–3 US FDA. Background Document for the Antiviral Drug Products Advisory Committee Meeting October 4 2001 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02_FDA-vor-iconazole.pdf [Accessed 2003 Aug 25] McGinnis MR, Pasarell L, Sutton DA, et al. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997 Aug; 41(8): 1832–4 Li RK, Ciblak MA, Nordoff N, et al. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000 Jun; 44(6): 1734–6 Gonzalez GM, Sutton DA, Thompson E, et al. In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi. Antimicrob Agents Chemother 2001 Feb; 45(2): 633–5 Murphy M, Bernard EM, Ishimaru T, et al. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997 Mar; 41(3): 696–8 Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000 Oct; 44(10): 2865–8 Sugar AM, Liu XP. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 2001 Feb; 45(2): 601–4 Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998 Oct; 36(10): 2950–6 Cacciapuoti A, Loebenberg D, Corcoran E, et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000 Aug; 44(8): 2017–22 Pfaller MA, Marco F, Messer SA, et al. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998 Apr; 30(4): 251–5 Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000 Jan; 44(1): 57–62 Marco F, Pfaller MA, Messer SA, et al. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia 1998; 141(2): 73–7 Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 2001 Feb; 45(2): 605–7 Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998 Oct; 42(10): 2726–30 Fung-Tomc JC, Huczko E, Minassian B, et al. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998 Feb; 42(2): 313–8 Dannaoui E, Meletiadis J, Meis JFG, et al. In vitro activity of conventional and new antifungals against zygomycetes. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto. Toronto, Canada: American Society for Microbiology, 2000 Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002 Jan; 346(4): 225–34 Marr KA. Empirical antifungal therapy: new options, new tradeoffs. N Engl J Med 2002 Jan; 346(4): 278–80 Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002 Jan; 346(4): 289–90 Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 Mar; 34(5): 563–71 Herbrecht R, Denning DW, Patterson TF, et al. Open, randomised comparison of voriconazole (VRC) and amphotericin b (AmB) followed by other licensed antifungal therapy (OLAT) for primary therapy of invasive aspergillosis (IA). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago. Chicago (IL): American Society for Microbiology, 2001 Munoz P, Marin M, Tornero P, et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000 Dec; 31(6): 1499–501 Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001 Nov; 33(9): 1447–54 Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997 May; 41(5): 1124–6 Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996 May; 40(5): 1314–6 Lutz JE, Clemons KV, Aristizabal BH, et al. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 1997 Jul; 41(7): 1558–61 Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001 Mar; 45(3): 857–69 Graybill JR, Bocanegra R, Najvar LK, et al. SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 1998 Oct; 42(4): 539–42 Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-sus-ceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997 Jul; 41(7): 1504–7 Connolly P, Wheat J, Schnizlein-Bick C, et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 1999 Feb; 43(2): 322–8 Connolly P, Wheat LJ, Schnizlein-Bick C, et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 2000 Oct; 44(10): 2604–8 Perfect JR, Cox GM, Dodge RK, et al. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996 Aug; 40(8): 1910–3 Hata K, Kimura J, Miki H, et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 1996 Oct; 40(10): 2237–42 Moore CB, Walls CM, Denning DW. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000 Feb; 44(2): 441–3 Yamazumi T, Pfaller MA, Messer SA, et al. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000 Oct; 44(10): 2883–6 Hata K, Kimura J, Miki H, et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1996 Oct; 40(10): 2243–7 Roberts J, Schock K, Marino S, et al. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000 Dec; 44(12): 3381–8 Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother 2002 Feb; 49(2): 353–7 Clemons KV, Martinez M, Calderon L, et al. Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob Agents Chemother 2002 Mar; 46(3): 922–4 Muller FM, Weig M, Peter J, et al. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 2000 Aug; 46(2): 338–40 Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002 Feb; 46(2): 556–7 Oakley KL, Moore CB, Denning DW. In-vitro activity of voriconazole against Aspergillus spp and comparison with itraconazole and amphotericin. Br J Antimicrob Chemother 1998 Jul; 42(1): 91–4 Bouffard FA, Zambias RA, Dropinski JF, et al. Synthesis and antifungal activity of novel cationic pneumocandin Bo derivatives. J Med Chem 1994 Jan; 37(2): 222–5 Thompson JR, Douglas CM, Li W, et al. A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol 1999 Jan; 181(2): 444–53 Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001 Jan; 45(1): 327–30 Graybill JR, Najvar LK, Montalbo EM, et al. Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob Agents Chemother 1998 Jan; 42(1): 151–3 Bartizal K, Scott T, Abruzzo GK, et al. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother 1995 May; 39(5): 1070–6 Feldmesser M, Kress Y, Mednick A, et al. The effect of the pneumocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000; 182: 1791–5 Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002 Jan; 46(1): 245–7 Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997 Feb; 41(2): 331–6 Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002 Jan; 46(1): 12–23 Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-in-duced immunosuppressed mice. Antimicrob Agents Chemother 2000 Sep; 44(9): 2310–8 Gonzalez GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001 Jun; 45(6): 1854–9 Schmatz DM, Powles MA, McFadden D, et al. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Antimicrob Agents Chemother 1995 Jun; 39(6): 1320–3 Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001 Nov; 55(9): 633–8 Maertens J, Raad I, Sable CA, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to amphotericin B (AMB), AMB lipid formulations (Lipid AMB), or azoles. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto. Toronto, Canada: American Society for Microbiology, 2000 Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001 Nov; 33(9): 1529–35 Matsumoto S, Wakai Y, Nakai T, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000 Mar; 44(3): 619–21 Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000 Mar; 44(3): 614–8 Ito M, Nozu R, Kuramochi T, et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000 Sep; 44(9): 2259–62 Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998 Nov; 42(11): 2898–905 Clemons KV, Sobel RA, Stevens DA. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrob Agents Chemother 2000 Feb; 44(2): 378–81 Obi K, Uda J, Iwase K, et al. Novel nikkomycin analogues: inhibitors of the fungal cell wall biosynthesis enzyme chitin synthase. Bioorg Med Chem Lett 2000 Jul; 10(13): 1451–4 Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999 Jun; 43(6): 1401–5 Clemons KV, Stevens DA. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob Agents Chemother 1997 Sep; 41(9): 2026–8 Stevens DA. Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother 2000 Sep; 44(9): 2547–8 Graybill JR, Najvar LK, Bocanegra R, et al. Efficacy of nikkomycin Z in the treatment of murine histoplasmosis. Antimicrob Agents Chemother 1998 Sep; 42(9): 2371–4 Rex JH, Walsh TJ, Nettleman M, et al. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 2001 Jul; 33(1): 95–106 Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982 Jan; 72(1): 101–11 Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989 Jun; 86 (6 Pt 1): 668–72 Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001 Oct; 14(4): 643–58 Espinel-Ingroff A, Bartlett M, Chaturvedi V, et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation: National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother 2001 Jun; 45(6): 1828–35 Denning DW, Radford SA, Oakley KL, et al. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997 Sep; 40(3): 401–14